Is CVE-2026-50034 actively exploited?

No active exploitation of CVE-2026-50034 has been confirmed so far. Continue monitoring, as exploit status can change.

Can CVE-2026-50034 be exploited remotely?

Partially. CVE-2026-50034 requires adjacent network access (same network segment) to exploit.

What is the CVSS score of CVE-2026-50034?

CVE-2026-50034 has a CVSS score of 6.5 (MEDIUM).

HOME VULNERABILITIESCVE-2026-50034

MEDIUM

CVE-2026-50034

CWE-319Published: June 19, 2026· Updated: Jun 22, 2026

6.5

CVSS v3.1

Official Description

An attacker within BLE communication range can passively intercept

wireless traffic and obtain sensitive health-related information,

including glucose measurement values.

NVD Source

Technical Analysis

CVE-2026-50034 requires adjacent network access, limiting remote exploitation but still posing risk in shared or local network environments.

The vulnerability requires no privileges and no user interaction, making it a prime target for automated exploitation campaigns and worm-like propagation.

A successful exploit results in complete confidentiality breach (data exposure), with a CVSS base score of 6.5.

CVSS v3.1 Vector Breakdown

Exploitability

Attack VectorAdjacent

Attack ComplexityLow

Privileges Req.None

User InteractionNone

ScopeUnchanged

Impact

ConfidentialityHigh

IntegrityNone

AvailabilityNone

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Exploit & PoC Resources

NO KNOWN EXPLOITNo public exploit confirmed at this time

Exploit-DB

Offensive Security exploit database

GitHub PoC Search

Community PoC repositories

Rapid7 / Metasploit

Metasploit module search

PacketStorm

Security advisories & exploits

External links open in a new tab. Always verify in a controlled environment before use.

News & Research Mentioning CVE-2026-50034

Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT

CISA Alerts· Jun 18, 2026

View CSAF Summary Successful exploitation of these vulnerabilities could allow an attacker to obtain sensitive health-related information and prevent legitimate users from establishing a connection with the device. The following versions of Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT are affected: Blood Glucose Monitoring System (Model No. APG-01 BT) 0x0110_v1.1.0 (CVE-2026-50034, CVE-2026-52866) CVSS Vendor Equipment Vulnerabilities v3 6.5 Apollo Pharmacy Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Cleartext Transmission of Sensitive Information, Missing Authorization Background Critical Infrastructure Sectors: Healthcare and Public Health Countries/Areas Deployed: India Company Headquarters Location: India Vulnerabilitie [xlite_meta score:73 src:CISA Alerts xlite_fp:a8c7a750538e2275ea8b101c510eb9fe37a577d1b98dcb09de66caf6a763a018]